Skip to main content
Journal cover image

Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).

Publication ,  Journal Article
Kandzari, DE; Labinaz, M; Cantor, WJ; Madan, M; Gallup, DS; Hasselblad, V; Joseph, D; Allen, A; Green, C; Hidinger, KG; Krucoff, MW ...
Published in: Am J Cardiol
September 15, 2003

Myocardial ischemic injury complicating acute myocardial infarction (AMI) and coronary revascularization procedures remains an unresolved clinical dilemma. In preclinical studies, treatment with pyridoxal-5'-phosphate monohydrate (MC-1), a vitamin B6 metabolite, has demonstrated cardioprotective effects. Sixty patients scheduled for elective percutaneous coronary intervention (PCI) who had clinically high-risk characteristics for ischemic complications were randomized to treatment with MC-1 or placebo in a 2:1 double-blinded fashion. The primary end point was defined as infarct size as measured by area under the curve creatine kinase MB (CK-MB) enzymes. Secondary end points included periprocedural ischemia as assessed by continuous electrocardiographic monitoring, 30-day major adverse cardiac events, and net clinical safety, which included liver function testing. The primary end point, median periprocedural CK-MB area under the curve, was reduced from 32.9 ng/ml in the placebo group to 18.6 ng/ml with MC-1 treatment (p = 0.038), reflecting a shift in the distribution of CK-MB. By categorical classification, the occurrence of 30-day nonfatal AMI did not differ between groups. There were no deaths, and 30-day composite adverse event rates were similar (17.9% MC-1 vs 15.0% placebo, p = 1.0). There were no significant differences in ischemia parameters per continuous electrocardiographic monitoring, and no safety issues were identified. In this phase II pilot study, treatment of high-risk patients who underwent PCI with MC-1 was associated with a decrease in the total amount of CK-MB released after PCI. These results support the evaluation of MC-1 in pivotal trials of patients at risk for developing myocardial ischemia, infarction, or reperfusion injury.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

September 15, 2003

Volume

92

Issue

6

Start / End Page

660 / 664

Location

United States

Related Subject Headings

  • Pyridoxal Phosphate
  • Necrosis
  • Myocardial Reperfusion Injury
  • Myocardial Ischemia
  • Middle Aged
  • Male
  • Humans
  • Female
  • Feasibility Studies
  • Double-Blind Method
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kandzari, D. E., Labinaz, M., Cantor, W. J., Madan, M., Gallup, D. S., Hasselblad, V., … Tcheng, J. E. (2003). Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol, 92(6), 660–664. https://doi.org/10.1016/s0002-9149(03)00818-x
Kandzari, David E., Marino Labinaz, Warren J. Cantor, Mina Madan, Dianne S. Gallup, Vic Hasselblad, Diane Joseph, et al. “Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).Am J Cardiol 92, no. 6 (September 15, 2003): 660–64. https://doi.org/10.1016/s0002-9149(03)00818-x.
Kandzari DE, Labinaz M, Cantor WJ, Madan M, Gallup DS, Hasselblad V, et al. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol. 2003 Sep 15;92(6):660–4.
Kandzari, David E., et al. “Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).Am J Cardiol, vol. 92, no. 6, Sept. 2003, pp. 660–64. Pubmed, doi:10.1016/s0002-9149(03)00818-x.
Kandzari DE, Labinaz M, Cantor WJ, Madan M, Gallup DS, Hasselblad V, Joseph D, Allen A, Green C, Hidinger KG, Krucoff MW, Christenson RH, Harrington RA, Tcheng JE. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol. 2003 Sep 15;92(6):660–664.
Journal cover image

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

September 15, 2003

Volume

92

Issue

6

Start / End Page

660 / 664

Location

United States

Related Subject Headings

  • Pyridoxal Phosphate
  • Necrosis
  • Myocardial Reperfusion Injury
  • Myocardial Ischemia
  • Middle Aged
  • Male
  • Humans
  • Female
  • Feasibility Studies
  • Double-Blind Method